- Home
- PII vs RARE Comparison
PII vs RARE Comparison
Compare PII & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PII
- RARE
- Stock Information
- Founded
- PII 1954
- RARE 2010
- Country
- PII United States
- RARE United States
- Employees
- PII N/A
- RARE N/A
- Industry
- PII Recreational Games/Products/Toys
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- PII Consumer Discretionary
- RARE Health Care
- Exchange
- PII Nasdaq
- RARE Nasdaq
- Market Cap
- PII 2.6B
- RARE 2.8B
- IPO Year
- PII 1987
- RARE 2014
- Fundamental
- Price
- PII $50.23
- RARE $27.34
- Analyst Decision
- PII Hold
- RARE Strong Buy
- Analyst Count
- PII 12
- RARE 15
- Target Price
- PII $41.00
- RARE $87.40
- AVG Volume (30 Days)
- PII 1.8M
- RARE 3.1M
- Earning Date
- PII 07-29-2025
- RARE 08-04-2025
- Dividend Yield
- PII 5.33%
- RARE N/A
- EPS Growth
- PII N/A
- RARE N/A
- EPS
- PII 0.71
- RARE N/A
- Revenue
- PII $7,072,600,000.00
- RARE $590,689,000.00
- Revenue This Year
- PII N/A
- RARE $18.94
- Revenue Next Year
- PII $4.00
- RARE $28.61
- P/E Ratio
- PII $70.92
- RARE N/A
- Revenue Growth
- PII N/A
- RARE 33.46
- 52 Week Low
- PII $30.92
- RARE $25.81
- 52 Week High
- PII $87.83
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- PII 61.36
- RARE 32.88
- Support Level
- PII $49.04
- RARE $25.81
- Resistance Level
- PII $53.83
- RARE $28.52
- Average True Range (ATR)
- PII 2.13
- RARE 1.66
- MACD
- PII 0.13
- RARE -0.43
- Stochastic Oscillator
- PII 56.36
- RARE 9.24
About PII Polaris Inc.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.